KRAS WT interactome analysis revealed moderate enrichment in the MAPK (p = 0.047) and PI3K-AKT (p = 0.032) pathways—canonical KRAS effectors driving proliferation in PAAD and CRC. This evidence concerns the gene KRAS and pancreatic adenocarcinoma.